A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer

Trial Profile

A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Futuximab (Primary) ; Futuximab/modotuximab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors EMD Serono
  • Most Recent Events

    • 29 Aug 2016 Status changed from completed to discontinued.
    • 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Mar 2015 Planned End Date changed from 1 Aug 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top